B-intervention	0	1	"
I-intervention	1	7	Tumour
I-intervention	8	14	marker
I-intervention	15	21	guided
I-intervention	21	22	"
I-intervention	23	30	salvage
I-intervention	31	40	treatment
O	41	49	prolongs
O	50	58	survival
O	59	61	of
O	62	68	breast
O	69	75	cancer
O	76	84	patients
O	84	85	:
O	86	91	final
O	92	98	report
O	99	101	of
O	102	103	a
O	104	105	7
O	105	106	-
O	106	110	year
O	111	116	study
O	116	117	.

O	118	128	Randomised
O	129	135	trials
O	136	138	on
O	139	145	breast
O	146	152	cancer
O	153	159	showed
O	160	162	no
O	163	174	significant
O	175	182	benefit
O	183	187	from
O	188	192	post
O	192	193	-
O	193	202	operative
O	203	209	follow
O	209	210	-
O	210	212	up
O	213	217	with
O	218	226	clinical
O	227	230	and
O	230	231	/
O	231	233	or
O	234	246	conventional
O	247	259	radiological
O	260	265	means
O	265	266	.

O	267	269	We
O	270	282	hypothesised
O	283	287	that
O	288	304	carcinoembryonic
O	305	312	antigen
O	313	314	(
O	314	317	CEA
O	317	318	)
O	318	319	,
O	320	326	tissue
O	327	338	polipeptyde
O	339	346	antigen
O	347	348	(
O	348	351	TPA
O	351	352	)
O	352	353	,
O	354	360	breast
O	361	367	cancer
O	368	378	associated
O	379	386	antigen
O	387	390	115
O	391	393	D8
O	393	394	/
O	394	397	DF3
O	398	399	(
O	399	403	CA15
O	403	404	.
O	404	405	3
O	405	406	)
O	407	413	tumour
O	414	420	marker
O	421	426	panel
O	427	429	is
O	430	439	sensitive
O	440	446	enough
O	447	450	for
O	451	464	significantly
O	465	477	anticipating
O	478	485	salvage
O	486	495	treatment
O	496	499	and
O	500	510	prolonging
O	511	519	survival
O	520	522	of
O	523	532	relapsing
O	533	539	breast
O	540	546	cancer
O	547	555	patients
O	555	556	.

O	557	561	From
O	562	569	October
O	570	574	1981
O	575	577	to
O	578	581	May
O	582	586	1999
O	586	587	,
B-total-participants	588	590	68
O	591	592	(
O	592	594	62
O	594	595	%
O	595	596	)
O	597	599	of
O	600	603	109
B-eligibility	604	612	patients
I-eligibility	613	617	with
I-eligibility	618	625	distant
I-eligibility	626	636	metastases
O	637	641	were
O	642	651	recruited
O	651	652	.

B-intervention-participants	653	659	Thirty
I-intervention-participants	659	660	-
I-intervention-participants	660	663	six
O	664	665	(
O	665	667	53
O	667	668	%
O	668	669	)
O	670	678	received
O	679	686	salvage
O	687	696	treatment
O	697	699	at
O	700	703	the
O	704	708	time
O	709	711	of
O	712	723	significant
O	724	732	increase
O	733	735	in
O	736	739	one
O	740	742	or
O	743	747	more
O	748	758	components
O	759	761	of
O	762	765	CEA
O	765	766	-
O	766	769	TPA
O	769	770	-
O	770	774	CA15
O	774	775	.
O	775	776	3
O	777	783	tumour
O	784	790	marker
O	791	796	panel
O	797	800	and
O	801	809	negative
O	810	822	instrumental
O	823	835	examinations
O	836	837	(
O	837	838	"
O	838	844	tumour
O	845	851	marker
O	852	858	guided
O	858	859	"
O	860	869	treatment
O	869	870	)
O	871	874	and
B-control-participants	875	877	32
O	878	879	(
O	879	881	47
O	881	882	%
O	882	883	)
O	884	888	were
O	889	896	treated
O	897	901	only
O	902	907	after
O	908	920	radiological
O	921	933	confirmation
O	934	936	of
O	937	947	metastases
O	948	949	(
B-control	949	961	conventional
I-control	962	971	treatment
O	971	972	)
O	972	973	.

O	974	977	The
O	978	988	prognostic
O	989	996	factors
O	997	999	of
O	1000	1003	the
O	1004	1007	two
O	1008	1014	groups
O	1015	1018	did
O	1019	1022	not
O	1023	1027	show
O	1028	1031	any
O	1032	1045	statistically
O	1046	1057	significant
O	1058	1068	difference
O	1068	1069	.

O	1070	1073	The
O	1074	1078	time
O	1079	1083	from
O	1084	1087	one
O	1088	1090	or
O	1091	1095	more
O	1096	1102	tumour
O	1103	1109	marker
O	1110	1118	increase
O	1119	1121	to
O	1122	1127	clear
O	1128	1136	clinical
O	1137	1140	and
O	1140	1141	/
O	1141	1143	or
O	1144	1156	radiological
O	1157	1162	signs
O	1163	1165	of
O	1166	1173	distant
O	1174	1184	metastases
O	1185	1186	(
B-outcome	1186	1190	lead
I-outcome	1191	1195	time
O	1195	1196	)
O	1197	1200	was
O	1201	1214	significantly
O	1215	1224	prolonged
O	1225	1227	in
O	1228	1231	the
O	1232	1234	36
O	1235	1243	patients
O	1244	1248	with
O	1249	1250	"
O	1250	1256	tumour
O	1257	1263	marker
O	1264	1270	guided
O	1270	1271	"
O	1272	1281	treatment
O	1282	1283	(
B-iv-cont-mean	1283	1285	17
I-iv-cont-mean	1285	1286	.
I-iv-cont-mean	1286	1287	3
O	1288	1289	+
O	1289	1290	/
O	1290	1291	-
B-iv-cont-sd	1292	1294	13
I-iv-cont-sd	1294	1295	.
I-iv-cont-sd	1295	1296	1
O	1297	1299	vs
O	1299	1300	.
B-cv-cont-mean	1301	1302	2
I-cv-cont-mean	1302	1303	.
I-cv-cont-mean	1303	1304	9
O	1305	1306	+
O	1306	1307	/
O	1307	1308	-
B-cv-cont-sd	1309	1310	2
I-cv-cont-sd	1310	1311	.
I-cv-cont-sd	1311	1312	9
I-cv-cont-sd	1313	1319	months
O	1319	1320	,
O	1321	1322	P
O	1323	1324	<
O	1325	1326	0
O	1326	1327	.
O	1327	1330	001
O	1330	1331	,
O	1332	1340	Wilcoxon
O	1341	1345	test
O	1345	1346	)
O	1347	1349	as
O	1350	1354	well
O	1355	1357	as
O	1358	1361	the
B-outcome	1362	1370	survival
I-outcome	1371	1377	curves
O	1378	1382	from
O	1383	1390	salvage
O	1391	1398	therapy
O	1399	1402	and
O	1403	1407	from
O	1408	1418	mastectomy
O	1419	1420	(
O	1420	1423	the
O	1424	1434	proportion
O	1435	1437	of
O	1438	1447	survivors
O	1448	1451	was
O	1451	1452	:
B-outcome	1453	1455	at
I-outcome	1456	1458	36
I-outcome	1459	1465	months
O	1466	1470	from
O	1471	1478	salvage
O	1479	1486	therapy
B-iv-bin-percent	1487	1489	28
I-iv-bin-percent	1489	1490	%
O	1491	1493	vs
O	1493	1494	.
B-cv-bin-percent	1495	1496	9
I-cv-bin-percent	1496	1497	%
O	1497	1498	,
O	1499	1500	P
O	1501	1502	=
O	1503	1504	0
O	1504	1505	.
O	1505	1509	0094
O	1509	1510	;
B-outcome	1511	1513	at
I-outcome	1514	1516	84
I-outcome	1517	1523	months
O	1524	1528	from
O	1529	1539	mastectomy
B-iv-bin-percent	1540	1542	42
I-iv-bin-percent	1542	1543	%
O	1544	1546	vs
O	1546	1547	.
B-cv-bin-percent	1548	1550	19
I-cv-bin-percent	1550	1551	%
O	1551	1552	,
O	1553	1554	P
O	1555	1556	=
O	1557	1558	0
O	1558	1559	.
O	1559	1563	0017
O	1563	1564	)
O	1564	1565	.

O	1566	1569	The
O	1570	1582	multivariate
O	1583	1586	Cox
O	1587	1595	analysis
O	1596	1602	showed
O	1603	1607	that
O	1608	1612	time
O	1613	1617	from
O	1618	1628	mastectomy
O	1629	1631	to
O	1632	1638	tumour
O	1639	1645	marker
O	1646	1654	increase
O	1655	1658	and
O	1659	1660	"
O	1660	1666	tumour
O	1667	1673	marker
O	1674	1680	guided
O	1680	1681	"
O	1682	1689	salvage
O	1690	1699	treatment
O	1700	1704	were
O	1705	1708	the
O	1709	1713	only
O	1714	1727	significantly
O	1728	1737	different
O	1738	1747	variables
O	1748	1749	(
O	1749	1750	P
O	1751	1752	=
O	1753	1754	0
O	1754	1755	.
O	1755	1760	00001
O	1761	1764	and
O	1765	1766	0
O	1766	1767	.
O	1767	1770	005
O	1770	1771	,
O	1772	1784	respectively
O	1784	1785	)
O	1785	1786	.

O	1787	1792	These
O	1793	1797	data
O	1798	1803	point
O	1804	1807	out
O	1808	1812	that
O	1813	1814	"
O	1814	1820	tumour
O	1821	1827	marker
O	1828	1834	guided
O	1834	1835	"
O	1836	1843	salvage
O	1844	1853	treatment
O	1854	1867	significantly
O	1868	1876	prolongs
O	1877	1884	disease
O	1884	1885	-
O	1885	1889	free
O	1890	1893	and
O	1894	1901	overall
O	1902	1911	survivals
O	1912	1914	of
O	1915	1924	relapsing
O	1925	1935	responsive
O	1936	1944	patients
O	1944	1945	.
